Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

verve therapeutics inc. - VERV

VERV

Close Chg Chg %
4.55 0.10 2.20%

Open Market

4.65

+0.10 (2.20%)

Volume: 560.47K

Last Updated:

Nov 21, 2024, 1:13 PM EDT

Trade Now

Company Overview: verve therapeutics inc. - VERV

VERV Key Data

Open

$4.55

 Day Range

4.44 - 4.69

52 Week Range

4.31 - 19.34

 Market Cap

$385.22M

Shares Outstanding

84.66M

 Public Float

63.09M

Beta

1.76

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$2.46

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.53M

  

VERV Performance

1 Week
 
 -5.01%
 
1 Month
 
 -23.79%
 
3 Months
 
 -7.89%
 
1 Year
 
 -62.46%
 
5 Years
 
 N/A
 

VERV Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 11
Full Ratings ➔

About verve therapeutics inc. - VERV

Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company was founded by Burt A. Adelman, Keith J. Joung, Sekar Kathiresan, Kiran Musunuru, Anthony Philippakis, Issi Rozen, and Barry Ticho in 2018 and is headquartered in Boston, MA.

VERV At a Glance

Verve Therapeutics, Inc.
201 Brookline Avenue
Boston, Massachusetts 02215
Phone 1-617-603-0070 Revenue 11.76M
Industry Biotechnology Net Income -200,068,000.00
Sector Health Technology 2023 Sales Growth 505.77%
Fiscal Year-end 12 / 2024 Employees 255
View SEC Filings

VERV Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 76.085
Price to Book Ratio 1.906
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -1.588
Enterprise Value to Sales 29.389
Total Debt to Enterprise Value 0.217

VERV Efficiency

Revenue/Employee 46,109.804
Income Per Employee -784,580.392
Receivables Turnover 1.994
Total Asset Turnover 0.016

VERV Liquidity

Current Ratio 17.239
Quick Ratio 17.239
Cash Ratio 16.861

VERV Profitability

Gross Margin 53.606
Operating Margin -1,897.636
Pretax Margin -1,699.209
Net Margin -1,701.548
Return on Assets -27.944
Return on Equity -34.781
Return on Total Capital -29.666
Return on Invested Capital -31.135

VERV Capital Structure

Total Debt to Total Equity 12.495
Total Debt to Total Capital 11.107
Total Debt to Total Assets 9.952
Long-Term Debt to Equity 10.795
Long-Term Debt to Total Capital 9.596
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Verve Therapeutics Inc. - VERV

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
- - 1.94M 11.76M
-
Sales Growth
- - - +505.77%
-
Cost of Goods Sold (COGS) incl D&A
1.33M 3.38M 6.71M 5.46M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.33M 3.38M 6.71M 5.46M
Depreciation
1.33M 3.38M 6.71M 5.46M
Amortization of Intangibles
- - - -
-
COGS Growth
+1,152.83% +154.29% +98.73% -18.72%
Gross Income
(1.33M) (3.38M) (4.77M) 6.30M
Gross Income Growth
-1,152.83% -154.29% -41.25% +232.14%
Gross Profit Margin
- - -245.75% +53.61%
-
2020 2021 2022 2023 5-year trend
SG&A Expense
39.30M 83.69M 160.92M 229.43M
Research & Development
35.37M 68.20M 130.09M 184.95M
Other SG&A
3.93M 15.49M 30.82M 44.48M
SGA Growth
+190.33% +112.96% +92.28% +42.57%
Other Operating Expense
- - - -
-
Unusual Expense
5.24M 33.39M (1.49M) (165.00K)
EBIT after Unusual Expense
(45.87M) (120.46M) (164.20M) (222.96M)
Non Operating Income/Expense
162.00K 142.00K 6.87M 23.17M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(45.70M) (120.31M) (157.33M) (199.79M)
Pretax Income Growth
-136.85% -163.25% -30.77% -26.99%
Pretax Margin
- - -8,105.82% -1,699.21%
-
Income Tax
- - 53.00K 275.00K
-
Income Tax - Current - Domestic
- - - 275.00K
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(45.70M) (120.31M) (157.39M) (200.07M)
Minority Interest Expense
- - - -
-
Net Income
(45.70M) (120.31M) (157.39M) (200.07M)
Net Income Growth
-136.85% -163.25% -30.81% -27.12%
Net Margin Growth
- - -8,108.55% -1,701.55%
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(45.70M) (120.31M) (157.39M) (200.07M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(45.70M) (120.31M) (157.39M) (200.07M)
EPS (Basic)
-0.9479 -2.4801 -2.9133 -3.1175
EPS (Basic) Growth
-136.86% -161.64% -17.47% -7.01%
Basic Shares Outstanding
48.22M 48.51M 54.02M 64.18M
EPS (Diluted)
-0.9479 -2.4801 -2.9133 -3.1175
EPS (Diluted) Growth
-136.86% -161.64% -17.47% -7.01%
Diluted Shares Outstanding
48.22M 48.51M 54.02M 64.18M
EBITDA
(39.30M) (83.69M) (158.98M) (217.67M)
EBITDA Growth
-190.33% -112.96% -89.96% -36.92%
EBITDA Margin
- - -8,190.42% -1,851.24%
-

Snapshot

Average Recommendation BUY Average Target Price 25.111
Number of Ratings 11 Current Quarters Estimate -0.684
FY Report Date 12 / 2024 Current Year's Estimate -2.458
Last Quarter’s Earnings -0.59 Median PE on CY Estimate N/A
Year Ago Earnings -3.12 Next Fiscal Year Estimate -2.793
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 12 7 12 11
Mean Estimate -0.68 -0.73 -2.46 -2.79
High Estimates -0.51 -0.60 -1.89 -2.05
Low Estimate -0.81 -0.87 -2.96 -3.61
Coefficient of Variance -14.48 -15.05 -9.83 -18.16

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 9 9 9
OVERWEIGHT 0 0 0
HOLD 2 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Verve Therapeutics Inc. - VERV

Date Name Shares Transaction Value
Jun 28, 2024 Burt A. Adelman Director 136,139 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 28, 2024 Lonnel Coats Director 136,139 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 28, 2024 Michael F. MacLean Director 136,139 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 28, 2024 Sheila A. Mikhail Director 136,139 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 28, 2024 Jodie P. Morrison Director 267,541 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 28, 2024 Krishna Yeshwant Director 136,139 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 28, 2024 Alexander Gery Cumbo Director 136,139 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 28, 2024 Ourania Tatsis Director 267,541 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jun 26, 2024 Troy Lister Chief Scientific Officer 32,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 16, 2024 Andrew D. Ashe See Remarks 342,509 Open market or private purchase of non-derivative security Non-derivative transaction at $6.26 per share 2,144,106.34
Feb 12, 2024 Burt A. Adelman Director 124,900 Bona fide gift 0.00
Feb 12, 2024 Burt A. Adelman Director 37,168 Bona fide gift 0.00
Feb 12, 2024 Burt A. Adelman Director 391,158 Bona fide gift 0.00
Feb 12, 2024 Burt A. Adelman Director N/A Bona fide gift 0.00
Feb 12, 2024 Burt A. Adelman Director 428,326 Bona fide gift 0.00

Verve Therapeutics Inc. in the News